Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 1221

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 2
Chunk 1221
---
opharmaceutical
and healthcare investment banking industry. He has assisted biotech and specialty pharma companies raise more than $10 billion in initial
public offerings, follow-on offerings, debt offerings, and private placements. He has served as a financial advisor on mergers, acquisitions,
and strategic alliance transactions with a total deal value of more than $10 billion. From July 2020 until December 2023, Mr. Carey was
co-founder and President of ACELYRIN, INC., a biopharmaceutical company developing life-changing drug therapies. Mr. Carey previously
served as Executive Vice President and Chief Business Officer at Horizon Therapeutics plc from March 2014 to September 2019, during which
Horizon Therapeutics deployed in excess of $3.5 billion to acquire or license eight commercial products and three products in development
and grew net sales from $74 million in 2013 to approximately $1.2 billion in 2018, a compound annual growth rate of 75%. Before Horizon,
he spent more than 11 years as Managing Director and Head of the Life Sciences Investment Banking Group at JMP Securities. Mr. Carey was
also Managing Director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities. He received his B.B.A. in Accounting
from the University of Notre Dame. Mr. Carey currently serves on the Board of Beyond Cancer Ltd. and Sangamo Therapeutics, Inc.

Our Board of Directors
believes that Mr. Carey’s experience and perspective advising the Company and other life sciences companies in connections with
financings and strategic transactions, as well as his depth of operating and senior management experience in our industry, provide him
with the qualifications and skills to serve as a director.

Robert
Scott Goodman, Director

Robert
Scott Goodman joined our Board of Directors in June 2025. Mr. Goodman brings more than 30 years of executive commercial leadership experience
and success spanning venture-backed emerging businesses to Fortune 50 companies. Most recently, he served on the Board of Directors of
Fourth Frontier, a pioneering health tech company, where he contributed to the company’s 510k FDA device approval and supported
a successful Series B financing. Mr. Goodman served as the Chief Commercial Officer for pharmaceutical company WEP Clinical from 2023-2024,
where he helped accelerate and increase total contract values and revenue growth by over 30% YOY. Mr. Goodman served as Division President
at BioTelemetry, where he led a $